title: Necrotizing fasciitis secondary to bevacizumab treatment for metastatic rectal adenocarcinoma.
abstract: Bevacizumab is a recombinant humanized monoclonal antibody that selectively blocks the activity of vascular endothelial growth factor (VEGF) receptor and it is used in metastatic colorectal patients. We present here a case of fatal necrotizing fasciitis in a patient during bevacizumab treatment for colorectal cancer. In our review of the literature, necrotizing fasciitis was not reported before or during bevacizumab treatment.
authors.affiliation: Department of Medical Oncology, Ankara Numune Education and Research Hospital, Ankara, Turkey.
authors.forename: Mehmet A N
authors.initials: MA
authors.lastname: Sendur
authors.affiliation: Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey.
authors.forename: Sercan
authors.initials: S
authors.lastname: Aksoy
authors.affiliation: Department of Medical Oncology, Ankara Numune Education and Research Hospital, Ankara, Turkey.
authors.forename: Nuriye Yıldırım
authors.initials: NY
authors.lastname: Özdemir
authors.affiliation: Department of Medical Oncology, Ankara Numune Education and Research Hospital, Ankara, Turkey.
authors.forename: Nurullah
authors.initials: N
authors.lastname: Zengin
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects* / Q000627:therapeutic use; D000068258:Bevacizumab; D003131:Combined Modality Therapy; D019115:Fasciitis, Necrotizing / Q000139:chemically induced*; D017809:Fatal Outcome; D006801:Humans; D008113:Liver Neoplasms / Q000556:secondary*; D008297:Male; D008875:Middle Aged; D012004:Rectal Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab
keywords: Adverse drug reactions; bevacizumab; colorectal cancer; necrotizing fasciitis